Big Number $46 million. That’s how much Pfizer earned in revenue from Adcetris sales in 2023, as more than 140,000 patients have been treated with the drug, according to the company.

ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma, and has been previously approved as a therapy for adult patients in the European Union (EU) in ...

Adcetris is the first drug approved for the Hodgkin's lymphoma since 1977. The FDA sped approval up under an accelerated, six month system reserved for therapies that show promising results in ...

Adcetris is approved for use in children ages 2 years and older with high risk cHL that has not been treated before. For this use, the typical dosage is 1.8 mg/kg once every 3 weeks.

The combination of Adcetris, Revlimid and Rituxan significantly increased overall survival compared with Revlimid/Rituxan alone in patients with relapsed/refractory diffuse large B-cell lymphoma ...

Adcetris was recently approved by the FDA in 2011, so it’s fairly new, but Kathleen, a local cancer survivor who relapsed three times, said the drug has been a miracle for her.

Adcetris is an antibody-drug conjugate (ADC) that is designed to be stable in the bloodstream but to release monomethyl auristatin E (MMAE) upon internalization into CD30-expressing tumor cells.

Adcetris is a standard of care for patients with certain lymphomas and is approved for seven indications in the U.S., with more than 55,000 patients treated since its first U.S. approval in 2011.

Adcetris is available as a 50mg/vial lyophilized powder for intravenous (IV) infusion in single-use vials. For more information call (855) 473-2436 or visit Adcetris.com.

Approval of Adcetris as a first line of treatment for patients with advanced lymphoma could push sales past $1 billion in the U.S. Seattle Genetics Inc. is a step closer to winning Food and Drug ...

ADCETRIS (brentuximab vedotin) was issued marketing authorization under the NOC/c policy based on results from a single-arm, phase II pivotal trial in HL patients with relapsed or refractory ...

ADCETRIS is contraindicated for patients with hypersensitivity to brentuximab vedotin and its excipients. In addition, combined use of ADCETRIS with bleomycin causes pulmonary toxicity.